Aardvark Therapeutics to Present at Upcoming Investor Conferences in November

Rhea-AI Summary

Aardvark Therapeutics (Nasdaq: AARD) will present at two investor conferences in November 2025: the Stifel 2025 Healthcare Conference in New York on Tuesday, November 11 at 4:40 p.m. ET, and the TD Cowen Treatment Advancements in Obesity & Related Disorders Summit (virtual) on Monday, November 24 at 3:00 p.m. ET. Live webcasts of both presentations will be available via the company investor website and archived for approximately one month after each presentation.

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present at the following conferences during November:

• Stifel 2025 Healthcare Conference in New York
  Presentation: Tuesday, November 11 at 4:40 p.m. ET

• TD Cowen Treatment Advancements in Obesity & Related Disorders Summit (virtual)
  Presentation: Monday, November 24 at 3:00 p.m. ET

Live webcasts of each presentation will be accessible on the company’s website, www.aardvarktherapeutics.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.

About Aardvark Therapeutics, Inc.
Aardvark is a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of PWS and metabolic diseases. Recognizing hunger (the discomfort from not having eaten recently) is a distinct neural signaling pathway separate from appetite (the reward-seeking, desirability of food), our programs explore therapeutic applications in hunger associated indications and potential complementary uses with anti-appetite therapies. Our lead compound, oral ARD-101, is in Phase 3 clinical development for the treatment of hyperphagia associated with PWS, a rare disease characterized by insatiable hunger. Aardvark is also developing ARD-201, a planned fixed-dose combination of ARD-101 with a DPP-4 inhibitor, with a goal of addressing some of the limitations of currently marketed GLP-1 therapies for the treatment of obesity and obesity-related conditions. For more information, visit aardvarktherapeutics.com.  

Forward-Looking Statements 
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements concerning: Aardvark’s business strategy, product candidates, ongoing clinical trials, planned clinical trials, likelihood of success, as well as plans and objectives of management for future operations. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to potential delays in the commencement, enrollment and completion of clinical trials; the risk that we may use our capital resources sooner than expected and that they may be insufficient to allow us to achieve our anticipated milestones; risks related to our dependence on third parties for manufacturing, shipping and clinical and preclinical trials; the risk of unfavorable clinical results; the risk that results from earlier clinical trials and preclinical studies may not necessarily be predictive of future results; and other risks and uncertainties, including the factors described under the “Risk Factors” section of Aardvark’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 that the Company filed with the Securities and Exchange Commission on August 13, 2025. When evaluating Aardvark’s business and prospects, careful consideration should be given to these risks and uncertainties. Any forward-looking statements contained in this press release are based on the current expectations of Aardvark’s management team and speak only as of the date hereof, and Aardvark specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, unless required by law.

Contact:
Carolyn Hawley, Inizio Evoke Comms
(619) 849-5382
Carolyn.hawley@inizioevoke.com

FAQ

When will Aardvark Therapeutics (AARD) present at the Stifel 2025 Healthcare Conference?

Aardvark will present on Tuesday, November 11, 2025 at 4:40 p.m. ET.

How can investors watch Aardvark Therapeutics (AARD) presentations in November 2025?

Live webcasts will be accessible on the company investor website and archived for about one month after each presentation.

What time is Aardvark Therapeutics (AARD) speaking at the TD Cowen obesity summit?

The virtual presentation is scheduled for Monday, November 24, 2025 at 3:00 p.m. ET.

Will Aardvark Therapeutics (AARD) provide recordings of the November 2025 presentations?

Yes. Archived recordings will be available on the investor section of the company website for approximately one month after each presentation.

Where is the Stifel 2025 Healthcare Conference presentation by Aardvark Therapeutics (AARD) being held?

The Stifel presentation will be held in New York; the specific session is on November 11, 2025 at 4:40 p.m. ET.

What topics will Aardvark Therapeutics (AARD) likely cover in the November 2025 investor presentations?

The company will present corporate and clinical-stage program updates relevant to its development of small-molecule therapeutics for metabolic diseases.